45 research outputs found

    SΓΆr William’ın muaşakasΔ±

    Get PDF
    Alexandre Dumas'nΔ±n HanΔ±mlara Mahsus Gazete'de yayΔ±mlanan SΓΆr William’ın MuaşakasΔ± adlΔ± romanΔ±nΔ±n ilk ve son tefrikalar

    ИсслСдованиС процСсса каталитичСской Π΄Π΅ΠΏΠ°Ρ€Π°Ρ„ΠΈΠ½ΠΈΠ·Π°Ρ†ΠΈΠΈ Π΄ΠΈΠ·Π΅Π»ΡŒΠ½Ρ‹Ρ… Ρ‚ΠΎΠΏΠ»ΠΈΠ²

    Get PDF
    ΠžΠ±ΡŠΠ΅ΠΊΡ‚ исслСдования – процСсс каталитичСской Π΄Π΅ΠΏΠ°Ρ€Π°Ρ„ΠΈΠ½ΠΈΠ·Π°Ρ†ΠΈΠΈ Π΄ΠΈΠ·Π΅Π»ΡŒΠ½Ρ‹Ρ… Ρ‚ΠΎΠΏΠ»ΠΈΠ². ЦСль Ρ€Π°Π±ΠΎΡ‚Ρ‹ Π·Π°ΠΊΠ»ΡŽΡ‡Π°Π΅Ρ‚ΡΡ Π² ΠΏΠΎΠ²Ρ‹ΡˆΠ΅Π½ΠΈΠΈ эффСктивности Ρ€Π°Π±ΠΎΡ‚Ρ‹ установки каталитичСской Π³ΠΈΠ΄Ρ€ΠΎΠ΄Π΅ΠΏΠ°Ρ€Π°Ρ„ΠΈΠ½ΠΈΠ·Π°Ρ†ΠΈΠΈ дизСльного Ρ‚ΠΎΠΏΠ»ΠΈΠ²Π° ΠΏΡƒΡ‚Π΅ΠΌ ΠΏΠΎΠ΄Π±ΠΎΡ€Π° ΠΎΠΏΡ‚ΠΈΠΌΠ°Π»ΡŒΠ½Ρ‹Ρ… тСхнологичСских Ρ€Π΅ΠΆΠΈΠΌΠΎΠ² с ΠΏΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ ΠΌΠ΅Ρ‚ΠΎΠ΄Π° матСматичСского модСлирования. Π’ процСссС исслСдования Π±Ρ‹Π»Π° создана модСль Ρ€Π΅Π°ΠΊΡ‚ΠΎΡ€Π° Π΄Π΅ΠΏΠ°Ρ€Π°Ρ„ΠΈΠ½ΠΈΠ·Π°Ρ†ΠΈΠΈ с использованиСм систСмы HYSYS, ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½Π° ΠΎΡ†Π΅Π½ΠΊΠ° влияния тСхнологичСских ΠΏΠ°Ρ€Π°ΠΌΠ΅Ρ‚Ρ€ΠΎΠ² Π½Π° процСсс каталитичСской Π΄Π΅ΠΏΠ°Ρ€Π°Ρ„ΠΈΠ½ΠΈΠ·Π°Ρ†ΠΈΠΈ. ΠŸΠΎΠ΄ΠΎΠ±Ρ€Π°Π½Ρ‹ ΠΎΠΏΡ‚ΠΈΠΌΠ°Π»ΡŒΠ½Ρ‹Π΅ Ρ‚Π΅ΠΌΠΏΠ΅Ρ€Π°Ρ‚ΡƒΡ€Ρ‹ процСсса Π΄Π΅ΠΏΠ°Ρ€Π°Ρ„ΠΈΠ½ΠΈΠ·Π°Ρ†ΠΈΠΈ для производства дизСльного Ρ‚ΠΎΠΏΠ»ΠΈΠ²Π° Π·ΠΈΠΌΠ½Π΅Π³ΠΎ ΠΈ арктичСского Π² зависимости ΠΎΡ‚ состава ΡΡ‹Ρ€ΡŒΡ.The object of research is the process of catalytic dewaxing of diesel fuels. The purpose of the work is to increase the efficiency of the catalytic hydrodewaxing of diesel fuel by selecting the optimal technological regimes using the mathematical modeling method. During the research, a model of a dewaxing reactor was developed using the HYSYS system, an assessment of the effect of process parameters on the catalytic dewaxing process was carried out. Optimum temperatures of the process of dewaxing for the production of winter and Arctic diesel oil, depending on the composition of the raw materials, were selected

    Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study

    Get PDF
    BACKGROUND: The aim of the study was to determine the maximal tolerated dose (MTD) of gemcitabine every two weeks concurrent to radiotherapy, administered during an aggressive program of sequential and simultaneous radiochemotherapy for locally advanced, unresectable non-small cell lung cancer (NSCLC) and to evaluate the efficacy of this regime in a phase II study. METHODS: 33 patients with histologically confirmed NSCLC were enrolled in a combined radiochemotherapy protocol. 29 patients were assessable for evaluation of toxicity and tumor response. Treatment included two cycles of induction chemotherapy with gemcitabine (1200 mg/m(2)) and vinorelbine (30 mg/m(2)) at day 1, 8 and 22, 29 followed by concurrent radiotherapy (2.0 Gy/d; total dose 66.0 Gy) and chemotherapy with gemcitabine every two weeks at day 43, 57 and 71. Radiotherapy planning included [(18)F] fluorodeoxyglucose positron emission tomography (FDG PET) based target volume definition. 10 patients were included in the phase I study with an initial gemcitabine dose of 300 mg/m(2). The dose of gemcitabine was increased in steps of 100 mg/m(2 )until the MTD was realized. RESULTS: MTD was defined for the patient group receiving gemcitabine 500 mg/m(2 )due to grade 2 (next to grade 3) esophagitis in all patients resulting in a mean body weight loss of 5 kg (SD = 1.4 kg), representing 8% of the initial weight. These patients showed persisting dysphagia 3 to 4 weeks after completing radiotherapy. In accordance with expected complications as esophagitis, dysphagia and odynophagia, we defined the MTD at this dose level, although no dose limiting toxicity (DLT) grade 3 was reached. In the phase I/II median follow-up was 15.7 months (4.1 to 42.6 months). The overall response rate after completion of therapy was 64%. The median overall survival was 19.9 (95% CI: [10.1; 29.7]) months for all eligible patients. The median disease-free survival for all patients was 8.7 (95% CI: [2.7; 14.6]) months. CONCLUSION: After induction chemotherapy, the maximum tolerated dose and frequency of gemcitabine was defined at 500 mg/m(2 )every two weeks in three cycles during a maximum of 7 weeks of thoracic radiotherapy for the phase II study. This regimen represents an effective and tolerable therapy in the treatment of NSCLC

    Автоматизированная систСма управлСния бизнСс-процСссами Π½Π° Π±Π°Π·Π΅ ΠΌΠ°Π»ΠΎΠ³ΠΎ прСдприятия

    Get PDF
    ΠŸΡ€ΠΎΠ΅ΠΊΡ‚ΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠ΅ систСмы Π°Π²Ρ‚ΠΎΠΌΠ°Ρ‚ΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ управлСния бизнСс-процСссами Π½Π° Π±Π°Π·Π΅ ΠΌΠ°Π»ΠΎΠ³ΠΎ прСдприятия ΠΏΠΎ производству пластика для 3D-ΠΏΠ΅Ρ‡Π°Ρ‚ΠΈ. ΠžΠ±ΡŠΠ΅ΠΊΡ‚ΠΎΠΌ исслСдования являСтся бизнСс-процСссы, ΠΏΡ€ΠΎΡ‚Π΅ΠΊΠ°ΡŽΡ‰ΠΈΠ΅ Π½Π° прСдприятии ΠΏΠΎ производству пластика для 3D-ΠΏΠ΅Ρ‡Π°Ρ‚ΠΈ ЦСлью Ρ€Π°Π±ΠΎΡ‚Ρ‹ являСтся Ρ€Π°Π·Ρ€Π°Π±ΠΎΡ‚ΠΊΠ° систСмы управлСния бизнСс-процСссами.Designing an automated business process management system based on a small plastic manufacturing enterprise for 3D printin
    corecore